Charles Cherington
CIK: 0001448698
Charles Cherington's purchase track record
How the stock did after each of Charles Cherington's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since December 2, 2022
Stock higher 6 months later
0%
3 months: 50%
Median 6-month return
-48.9%
3 months: -9.3%
Beat the S&P 500
0%
median -61.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/10/2026 | ERNA | $2.00M | +55.0% | -43.4% | +11.3% |
| 6/9/2025 | ERNA | $2.22M | -56.5% | -54.4% | +14.0% |
| 4/2/2025 | ERNA | $394K | -30.5% | -60.0% | +18.3% |
| 12/2/2022 | ERNA | $859K | +11.8% | -39.4% | +5.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ERNA | ▲ Buy | Open Market | 4,000,000 | $2.0M | 2/10/2026 | View on chart |
| ERNA | ▲ Buy | Open Market | 21,241,163 | $2.2M | 6/9/2025 | View on chart |
| ERNA | ▲ Buy | Open Market | 3,768,397 | $394K | 4/2/2025 | View on chart |
| ERNA | ▲ Buy | Open Market | 261,756 | — | 10/29/2024 | View on chart |
| ERNA | ▲ Buy | Open Market | 4,768,783 | — | 10/29/2024 | View on chart |
| ERNA | ▲ Buy | Open Market | 1,237,762 | — | 10/29/2024 | View on chart |
| ERNA | ▲ Buy | Open Market | 5,420,823 | — | 10/29/2024 | View on chart |
| ERNA | ▲ Buy | Open Market | 1,562,988 | — | 10/29/2024 | View on chart |
| ERNA | ▼ Sell | Other | 2,819,546 | $1.4M | 10/29/2024 | View on chart |
| ERNA | ▲ Buy | Open Market | 261,756 | $859K | 12/2/2022 | View on chart |
| ERNA | ▼ Sell | Other | 92 | $0 | 6/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Ernexa Therapeutics reports safety data and new oncology leadership
Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.
Ernexa Therapeutics reports safety data and new oncology leadership. Ernexa announced that Dr. Robert J. Spiegel has joined the company as a senior executive, strengthening its oncology focus. The company also released safety data from three IND‑enabling studies of its lead iMSC therapy ERNA‑101, showing encouraging results that move the program toward a planned IND filing in Q4 2026. ERNA‑101 was selected for the Emerging Track at the 2026 Cell & Gene Meeting, highlighting its visibility in the cell‑therapy field.